{"data":{"id":2633,"lang":"en","title":"Pfizer Raises 2026 Guidance After Q3 Beat, Even as Revenue Stays Flat at $16.58 Billion","summary":"Pfizer posted adjusted EPS of $0.87 against $0.73 expected and lifted full-year revenue guidance to $62-64 billion.","category":"business","category_label":"Business","published_at":"2026-11-04T07:00:58Z","updated_at":"2026-11-04T07:00:58Z","url":"https://techtools.cz/tools/news/article/2633-pfizer-raises-2026-guidance-after-q3-beat-even-as-revenue-stays-flat-at-16-58","api_url":"https://techtools.cz/news-api/v1/articles/2633?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/2633.md?lang=en","image_url":"https://images.unsplash.com/photo-1611974789855-9c2a0a7236a3?w=800","word_count":163,"reading_time_minutes":1,"sources":[{"url":"https://www.cnbc.com/2026/11/03/pfizer-pfe-earnings-q3-2026.html","domain":"cnbc.com"}],"translation":{"lang":"cs","id":2707,"title":"Pfizer zvyšuje výhled na rok 2026 po překonání odhadů za 3. čtvrtletí, tržby zůstávají na 16,58 miliardy dolarů","url":"https://techtools.cz/tools/news/clanek/2707-pfizer-zvysuje-vyhled-na-rok-2026-po-prekonani-odhadu-za-3-ctvrtleti-trzby","api_url":"https://techtools.cz/news-api/v1/articles/2707?lang=cs"},"content":"Pfizer reported third-quarter adjusted earnings of $0.87 per share, well above the $0.73 analysts expected, on revenue of $16.58 billion, roughly flat year over year but ahead of the $15.87 billion forecast. GAAP net income fell to $3.24 billion, or $0.56 per share, from $3.54 billion a year earlier.\n\nThe company raised its 2026 revenue guidance to $62-64 billion from $60.5-62.5 billion and adjusted EPS to $2.95-$3.05 from $2.80-$3.00, a range that absorbs a one-time $650 million charge (about $0.10 per share) tied to the Innovent Biologics licensing deal. Eliquis sales rose 25% to $2.52 billion, Padcev reached $720 million, and newly launched and acquired products brought in $3.8 billion, up 32% operationally. Comirnaty ($808 million) and Paxlovid ($449 million) both beat estimates.\n\nPfizer targets about $9.7 billion in net cost savings through 2029 and is leaning on acquisitions, new cancer drugs and the Metsera weight-loss deal for growth. Cecile Guegan became CFO this month after Dave Denton left for Nike."}}